Healthcare Industry News:  Gate Pharmaceuticals 

Devices Biopharmaceuticals Drug Delivery Ophthalmology

 News Release - April 29, 2010

EyeGate Pharma Establishes Research Collaboration With GlaxoSmithKline to Deliver Medicines Using the EyeGate(R) II Delivery System

WALTHAM, MA--(HSMN NewsFeed) - EyeGate Pharma, the leader in non-invasive ocular drug delivery, today announces that they have established a research collaboration with GlaxoSmithKline (GSK) to evaluate the delivery of several GSK therapies to the anterior (front) and posterior (back) tissues of the eye using the EyeGate® II delivery system. Specific terms of the agreement were not disclosed.

Stephen From, President and Chief Executive Officer of EyeGate Pharma, commented, "EyeGate has developed a unique, non-invasive system that delivers therapeutics for ocular diseases. Our research collaboration with GlaxoSmithKline seeks to demonstrate the ability of EyeGate's proprietary technology in delivering GSK molecules targeted to areas of the eye."

Currently available ocular drug delivery options, which include topical drops and intravitreal injections, have limitations and associated risks. Ophthalmic drops are poorly absorbed into ocular tissues and can result in significant systemic concentrations. Intravitreal injections can lead to hemorrhaging, retinal detachment, endophalmitis, and other complications. To address the need for improved ocular drug delivery, EyeGate Pharma has developed a novel, non-invasive device that uses low-level electrical current to deliver drug substances to targeted areas of the eye.

EyeGate is the first company to conduct multiple controlled clinical trials to assess the safety and efficacy of iontophoresis technology to deliver therapeutics into the eye. EyeGate has successfully completed two Phase II studies of EGP-437, a corticosteroid solution administered by the EyeGate® II delivery system: one in dry eye syndrome (DES) patients and one in anterior uveitis patients.

About Iontophoresis as a Drug Delivery Approach

The EyeGate® II Delivery System works through iontophoresis, which occurs when an applied electric field enhances the mobility of molecules through cells and tissues primarily through electrochemical repulsion. These principles can be applied to anionic and cationic molecules. To deliver a therapeutic to both the anterior (front) and posterior (back) tissues of the eye, the drug must be specially adapted and formulated for iontophoretic delivery. EyeGate has concentrated its efforts on optimizing the EyeGate® II Delivery System to administer a wide range of therapeutics while developing a highly specialized laboratory dedicated to formulating drugs for iontophoretic delivery.

About EyeGate Pharma

EyeGate Pharmaceuticals, Inc. is focused on developing treatments for unmet ocular medical needs by employing the EyeGate® II Ocular Drug Delivery System, a non-invasive drug delivery technology. The EyeGate® II delivery system is compatible with a wide range of therapeutics; therefore, it has the potential to address many anterior and posterior segment diseases. EyeGate® II has been studied in over 200 subjects and is the first ocular iontophoretic system to have completed Phase II studies (Dry Eye and Uveitis). For more information, please visit www.eyegatepharma.com.


Source: EyeGate Pharma

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.